2-(3-chloro-4-methylphenyl)-5-methyl-2,4-dihydropyrazol-3-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-chloro-4-methylphenyl)-5-methyl-2,4-dihydropyrazol-3-one
• 英文别名: 1-(3-Chloro-4-methylphenyl)-3-methyl-2-pyrazolin-5-one；Cambridge id 6034877；2-(3-chloro-4-methylphenyl)-5-methyl-4H-pyrazol-3-one
• 化学式: C₁₁H₁₁ClN₂O
• mdl: MFCD01882749
• 分子量: 222.674
• InChiKey: UKTMRPNPEMPQMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-chloro-4-methylphenyl)-5-methyl-2,4-dihydropyrazol-3-one 、 4,4'-(but-2-yne-1,4-diylbis(oxy))bis(4-methylcyclohexa-2,5-dien-1-one) 在 dipotassium peroxodisulfate 、 silver hexafluoroantimonate 、 sodium hexaflorophosphate 、 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 三甲基乙酸 作用下， 反应 60.0h， 以58%的产率得到(3S,3aS,7aS)-3-((S)-8-chloro-2,7-dimethyl-5-(((1-methyl-4-oxocyclohexa-2,5-dien-1-yl)oxy)methyl)-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-yl)-7a-methyl-2,3,3a,7a-tetrahydrobenzofuran-5(4H)-one
  参考文献：
  名称：

  铑（III）催化的CH活化引发的1,6-烯炔的多环分子的高度立体选择性组装

  摘要：

  研究了Rh（III）催化吡唑啉酮与1，6-烯炔的C–H活化。通过使用对称的烯炔偶合剂可轻松解决C–H激活/炔烃插入的区域选择性，并实现了C–H激活触发的级联反应，其中涉及炔烃插入，互变异构和双环化，从而提供了一类结构复杂的多环架构。这种级联反应可在高区域选择性和立体专一性上耐受广泛的底物范围，并在一次操作中提供三个新的化学键和四个手性中心。进行了多环支架的各种衍生化，为产物提供了足够的空间用于进一步的功能转化。

  DOI：

  10.1021/acs.orglett.8b01099
• 作为产物：
  描述：

  双乙烯酮 生成 2-(3-chloro-4-methylphenyl)-5-methyl-2,4-dihydropyrazol-3-one
  参考文献：
  名称：

  BERTHOLD, R.

  摘要：

  DOI：

文献信息

• Thrombopoietin mimetics
  申请人：——

  公开号：US20040019190A1

  公开（公告）日：2004-01-29

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy- 1 -azobenzene derivative.

  发明了非肽类TPO类似物。还发明了用于制备目前发明的化合物的新工艺和中间体。还发明了一种治疗血小板减少症的方法，包括给予需要的哺乳动物，包括人类，有效量的选择性羟基-1-偶氮苯衍生物。
• Synthesis of Pyrazolo[1,2-<i>a</i>]cinnolines<i>via</i>a Rhodium-Catalyzed Oxidative Coupling Approach
  作者：Li Xing、Zhoulong Fan、Chengyu Hou、Guoping Yong、Ao Zhang

  DOI：10.1002/adsc.201301009

  日期：2014.3.24

  An efficient synthetic strategy for the unique class of pyrazolo[1,2‐a]cinnolines was developed through a rhodium‐catalyzed oxidative coupling of N‐aryl‐1H‐pyrazol‐5(4H)‐ones with internal alkynes. This protocol features use of the pyrazolone function in the substrate as an intrinsic directing group, hexafluoroisopropyl alcohol (HFIP) as the solvent, and mild reaction conditions as well as a wide substrate

  为唯一的类吡唑并的有效的合成策略[1,2一]噌啉通过的铑催化的氧化偶合开发ñ -芳基- 1 H ^ -吡唑-5-（4 ħ） -酮与内部炔烃。该方案的特征是在底物中使用吡唑啉酮功能作为固有的导向基团，在溶剂中使用六氟异丙醇（HFIP），反应条件温和，并且底物范围广。
• Palladium-catalyzed double C–H activation: one-pot synthesis of benzo[c]pyrazolo[1,2-a]cinnolin-1-ones from 5-pyrazolones and aryl iodides
  作者：Zhoulong Fan、Kui Wu、Li Xing、Qizheng Yao、Ao Zhang

  DOI：10.1039/c3cc47989g

  日期：——

  A palladium-catalyzed one-pot dual C–H activation approach to construct benzo[c]pyrazolo[1,2-a]cinnolin-1-ones is successfully developed.

  一种钯催化的一锅法双C-H活化方法成功地用于构建苯并[c]吡唑并[1,2-a]喹啉-1-酮。
• PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR INFLAMMATORY INTESTINAL DISEASES
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1553087A1

  公开（公告）日：2005-07-13

  The object of the present invention is to provide a medicament useful for preventing and/or treating inflammatory bowel disease. The present invention provides a medicament for preventing and/or treating inflammatory bowel disease which comprises as an active ingredient a pyrazolone derivative represented by the following formula (I) or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof: wherein R1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R1 and R2 are combined with each other to represent an alkylene group; and R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.

  本发明的目的是提供一种用于预防和/或治疗炎性肠病的药物。本发明提供了一种药物，用于预防和/或治疗炎性肠病，其包括以下式（I）所表示的吡唑酮衍生物作为活性成分，或其生理上可接受的盐，或其水合物或溶剂化合物：其中R1表示氢原子，芳基，烷基或烷氧羰基烷基；R2表示氢原子，芳氧基，芳硫基，烷基或羟基烷基；或R1和R2结合在一起表示烷基；R3表示氢原子，烷基，环烷基，羟基烷基，苄基，萘基，苯基或苯基，其被1至3个取代基所取代，所述取代基被选自羟基烷基，烷氧基，羟基烷氧基，烷氧羰基，烷硫基，烷基氨基，二烷基氨基，卤素原子，三氟甲基基团，羧基，氰基，羟基，硝基，氨基和乙酰胺基。
• AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20170273949A1

  公开（公告）日：2017-09-28

  It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.

  本发明的目的是提供一种新型药物，用于预防和/或治疗由眼部血管生成引起的眼科疾病。根据本发明，提供了一种用于预防和/或治疗由眼部血管生成引起的眼科疾病的药物，其包括作为活性成分的吡唑酮衍生物，如3-甲基-1-苯基-2-吡唑啉-5-酮，或其生理上可接受的盐，或其水合物或溶剂化物。